Profile data is unavailable for this security.
About the company
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
- Revenue in EUR (TTM)493.25m
- Net income in EUR35.83m
- Incorporated1967
- Employees2.81k
- LocationBoiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
- Phone+33 478456100
- Fax+33 478456291
- Websitehttps://www.boiron.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hunan Fangsheng Pharmaceutical Co Ltd | 213.56m | 27.52m | 553.11m | 1.69k | 19.76 | 2.89 | -- | 2.59 | 0.5026 | 0.5026 | 3.87 | 3.44 | 0.5372 | 1.44 | 6.24 | 998,562.10 | 6.67 | 5.39 | 11.80 | 9.37 | 68.22 | 66.91 | 12.43 | 8.95 | 0.472 | 14.06 | 0.3458 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| ScinoPharm Taiwan Ltd | 96.56m | 11.35m | 553.45m | 1.01k | 48.88 | 1.89 | 22.47 | 5.73 | 0.5084 | 0.5084 | 4.33 | 13.12 | 0.2871 | 1.27 | 6.63 | -- | 3.37 | 2.33 | 3.69 | 2.51 | 38.89 | 41.09 | 11.76 | 9.10 | 5.00 | -- | 0.0592 | 109.25 | -2.39 | -2.00 | -18.73 | -8.31 | 16.90 | -9.35 |
| Adcock Ingram Holdings Limited | 493.04m | 41.62m | 555.43m | 2.39k | 12.81 | 1.65 | -- | 1.13 | 5.26 | 5.26 | 62.36 | 40.94 | 1.16 | 2.57 | 4.50 | -- | 9.80 | 10.24 | 13.97 | 14.44 | 33.38 | 30.34 | 8.44 | 9.05 | 0.9267 | -- | 0.0493 | 41.41 | 5.60 | 6.38 | -9.39 | 3.37 | -9.93 | 6.58 |
| Revance Therapeutics Inc | 219.46m | -255.43m | 559.18m | 597.00 | -- | -- | -- | 2.55 | -3.17 | -3.21 | 2.64 | -1.24 | 0.4466 | 1.35 | 9.18 | 408,542.70 | -51.97 | -55.55 | -61.40 | -63.20 | 71.53 | -- | -116.39 | -304.96 | 3.01 | -22.09 | 1.41 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 222.53m | -4.79m | 570.24m | 2.65k | -- | 1.02 | -- | 2.56 | -0.0045 | -0.0045 | 0.2077 | 0.5212 | 0.1506 | 0.9641 | 1.98 | 671,173.20 | -1.77 | -6.85 | -2.68 | -9.10 | 65.91 | 75.81 | -11.78 | -36.23 | 1.52 | -1.39 | 0.181 | -- | -14.70 | -8.60 | 97.23 | -- | 0.9325 | -- |
| Boiron SA | 493.25m | 35.83m | 571.98m | 2.81k | 15.80 | 1.44 | 10.33 | 1.16 | 2.06 | 2.06 | 28.41 | 22.67 | 0.715 | 1.40 | 5.26 | 175,533.10 | 4.92 | 4.59 | 6.16 | 5.76 | 72.60 | 74.02 | 6.88 | 6.80 | 1.50 | -- | 0.0338 | 53.86 | -7.67 | -3.98 | -19.80 | -9.01 | -17.68 | -1.42 |
| Pharmanutra SpA | 106.64m | 14.50m | 573.11m | 112.00 | 39.25 | 10.38 | 32.37 | 5.37 | 1.51 | 1.51 | 11.09 | 5.70 | 0.9827 | 0.6257 | 4.40 | 1,015,648.00 | 13.36 | 18.39 | 17.76 | 24.80 | 95.63 | 96.36 | 13.59 | 17.77 | 1.84 | 41.91 | 0.3305 | 52.51 | 21.13 | 16.51 | -14.73 | 8.44 | 75.71 | 11.20 |
| Shandong Boan Biotechnology Co Ltd | 91.30m | 7.84m | 574.77m | 813.00 | 69.76 | 3.09 | 34.55 | 6.30 | 0.1332 | 0.1332 | 1.55 | 3.00 | 0.3069 | 1.10 | 2.60 | 972,753.60 | 2.63 | -- | 3.43 | -- | 74.10 | -- | 8.59 | -- | 1.03 | 4.01 | 0.3224 | -- | 19.80 | -- | 64.02 | -- | -- | -- |
| Sinovac Biotech Ltd | 386.20m | -117.63m | 575.79m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Consun Pharmaceutical Group Ltd | 347.39m | 106.08m | 581.32m | 3.18k | 5.23 | 1.24 | 5.00 | 1.67 | 1.14 | 1.14 | 3.73 | 4.82 | 0.5209 | 2.00 | 11.77 | 962,320.60 | 15.97 | 12.04 | 23.24 | 19.25 | 74.22 | 74.55 | 30.66 | 24.89 | 2.80 | -- | 0.1144 | 40.84 | 10.71 | 7.03 | 14.88 | 11.01 | -22.93 | 18.43 |
Data as of Sep 18 2024. Currency figures normalised to Boiron SA's reporting currency: Euro EUR
4.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Financi�re de l'�chiquier SAas of 27 Mar 2024 | 238.57k | 1.36% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 131.41k | 0.75% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 83.74k | 0.48% |
| DNCA Finance SAas of 31 Mar 2023 | 74.85k | 0.43% |
| HC Capital Advisors GmbHas of 30 Jun 2024 | 72.12k | 0.41% |
| HMG Finance SAas of 28 Mar 2024 | 70.95k | 0.40% |
| Sycomore Asset Management SAas of 31 Jul 2024 | 68.67k | 0.39% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 47.88k | 0.27% |
| Amplegest SASas of 31 Aug 2023 | 24.91k | 0.14% |
| Chaussier Gestion SAas of 28 Jun 2024 | 19.00k | 0.11% |
More ▼
Data from 29 Feb 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
